Cardiff Oncology, Inc.

Cardiff Oncology, Inc. is a California-based clinical-stage oncology company specializing in developing innovative cancer treatments. The company's lead drug candidate, onvansertib, is an oral selective Polo-like Kinase 1 Inhibitor designed for anti-cancer therapeutics. Additionally, Cardiff Oncology's product pipeline includes CY140, a promising inhibitor of PLK1, PLK2, and PLK3, currently in phase 1/2 studies for solid tumors and leukemias, as well as clinical trials for metastatic colorectal cancer and TROV-054, a Phase 1b/2 drug for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers, positioning itself as a key player in the oncology drug development market.